AMED Amedeo Res

RNS No 2657d
CHIROSCIENCE GROUP PLC
8th February 1999
 
 
    CHIROSCIENCE APPOINTS HEAD OF INVESTOR RELATIONS AND
                  CORPORATE COMMUNICATIONS
 
Chiroscience Group plc announces today the appointment of Mr
David  Dible  as  Head of Investor Relations  and  Corporate
Communications with effect from 1 March 1999. He will report
directly to Dr John Padfield, Chief Executive.
 
Mr  Dible is a biological scientist who has a broad range of
experience   in  healthcare,  equity  research   and,   most
recently,  business development and investor  relations.  He
has  worked  in  the UK with Wood Mackenzie, Edinburgh  Fund
Managers,  Baring Securities and SG Warburg  Securities,  in
Japan with Hoare Govett, and in Sweden with Arjo AB. David's
most  recent  role  was  as Investor Relations  Manager  for
Scotia Holdings PLC.
 
Dr  John  Padfield, Chief Executive Officer of  Chiroscience
Group plc , commented :
 
"I  am  delighted  that  we have been  able  to  appoint  an
individual  with  the very broad range  of  experience  that
David  has  developed. He will work closely with myself  and
other members of the Board to continue to communicate to all
external  audiences the important progress  that  the  Group
will  make  as  we  seek to build Europe's premier  emerging
pharmaceutical company."
 
For further information contact:

Dr John Padfield, Chief Executive        Giles Sanderson
Chiroscience Group plc                   Financial Dynamics
Tel: +44 (0)1223 420430                  Tel: +44 (0)171 831 3113
http://www.chiroscience.com
 
Chiroscience Group plc

Chiroscience  is  an emerging pharmaceutical  company  which
uses  its  diverse technology platform to discover,  develop
and bring to market novel medicines for improved healthcare.
It  has  three  businesses: Chiroscience R&D,  Rapigene  and
ChiroTech.
 
Chiroscience  R&D's  focus is on innovative  small  molecule
drugs  and related diagnostics in the therapeutic  areas  of
inflammatory   disease,  pain,  osteoporosis,   cancer   and
autoimmune  diseases.  Its technology  platform  allows  the
conception  and  development of receptor-based  and  enzyme-
inhibiting  small  molecule drugs with high  selectivity  of
action.   Rapigene is involved in the creation and provision
of  genomic  technologies and services to partner  companies
and  to  Chiroscience's drug discovery programmes.  Its  DNA
analysis  systems comprise of DNA hybridization, DNA  arrays
and   mass  spectrometry  tags.  ChiroTech  provides  chiral
technology   services   to   pharmaceutical   and    related
industries, including Chiroscience R&D.
 
Chiroscience  Group  plc  is  listed  on  the  London  Stock
Exchange  and is based in Cambridge and Stevenage,  UK,  and
Seattle, Washington, USA.
 
Chiroscience financial highlights for the six months  to  31
August 1998 (unaudited):

*    Revenues increased to #11.4m (H1 1997: #9.2m); net loss
     for the period #11.4m (H1 1997: #14.4m)

*    ChiroTech contributed sales of #6.8m (H1 1997: #5.9m);
     Chiroscience's drug discovery business contributed revenues
     of #4.5m (H1 1997: #3.3m).

*    Investment in research and development of  #13.5m  (1H
     1997: #19.0m).

*    Current cash reserves of #59m as at 24 September 1998.
 

END

APPGIGBDBDGCCCI

Grafico Azioni Amedeo Res (LSE:AMED)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Amedeo Res (LSE:AMED)
Storico
Da Lug 2023 a Lug 2024